Status:
COMPLETED
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vaccines, Pneumococcal
Eligibility:
All Genders
42-98 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with ro...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy 2-month-old infants
- Available for the entire study period
- Exclusion criteria:
- Previous vaccination with any vaccine before the start of the study
- Known contraindication to vaccination
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
619 Patients enrolled
Trial Details
Trial ID
NCT00368966
Start Date
October 1 2006
End Date
July 1 2008
Last Update
August 16 2012
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
A Coruña, A Coruna, Spain, 15006
2
Ferrol, A Coruna, Spain, 15405
3
Santiago de Compostela, A Coruna, Spain, 15706
4
Almería, Almeria, Spain, 04007